NEW YORK (GenomeWeb) – Canadian biopharmaceutical firm BiOasis last week announced that it has thrown its hat into the RNAi therapeutics ring and aims to advance an siRNA-based drug into Phase I testing before the end of next year.

While BiOasis hasn't made a final decision on what will be its first RNAi candidate, the firm recently presented limited data showing that its delivery technology could successfully carry siRNAs targeting Nox4, a gene involved in the generation of reactive oxygen species, across the blood-brain barrier (BBB).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.